GLP-1 Pipeline 2026: Every Next-Gen Drug in Development

Quick answer: The GLP-1 pipeline in 2026

The GLP-1 drug pipeline is the most active in all of pharma. As of August 2026, 190 obesity-related products are in development. Five are FDA-approved (Wegovy, Zepbound, Wegovy pill, Wegovy HD, Foundayo), and a wave of next-generation drugs is advancing through trials. The three closest to approval are:

• CagriSema (Novo Nordisk) — under FDA review, decision expected late 2026
• Retatrutide (Eli Lilly) — Phase 3 complete, BLA filing Q1 2027
• Survodutide (Boehringer/Zealand) — Phase 3 complete, filing ~2026-27

These drugs promise weight loss of 16-28%, potentially exceeding everything currently on the market.

The complete GLP-1 pipeline tracker

Deep dive: The 5 most important pipeline drugs

1. Retatrutide — the triple agonist powerhouse

Retatrutide is the most exciting drug in the pipeline. As a triple agonist targeting GLP-1, GIP, and glucagon receptors, it achieves weight loss through three complementary pathways:

• GLP-1: Suppresses appetite and slows digestion
• GIP: Enhances insulin secretion and may improve tolerability
• Glucagon: Increases energy expenditure and promotes liver fat burning

The TRIUMPH-1 Phase 3 trial reported 28.3% average weight loss at 80 weeks on the 12 mg dose, with up to 30.3% at 104 weeks in a BMI ≥ 35 extension. An extraordinary 45.3% of participants achieved ≥ 30% weight loss. Eli Lilly plans a BLA filing in Q1 2027.

Additional trial results: TRIUMPH-2 (T2D population) showed 20.8% weight loss, and TRIUMPH-3 (cardiovascular disease population) showed 22.6%. Full TRIUMPH-2 data will be presented at EASD in September 2026.

2. CagriSema — the amylin + semaglutide combination

CagriSema combines cagrilintide (an amylin analog) with semaglutide in a single weekly injection. Amylin is a different gut hormone than GLP-1 — it promotes satiety through a distinct pathway, making CagriSema mechanistically unique.

The REDEFINE-1 Phase 3 trial showed 22.7% weight loss at 68 weeks. While impressive, this was below Novo Nordisk's ~25% target. The NDA was filed in December 2025, and a FDA decision is expected in late 2026. CagriSema could become the first amylin-based obesity drug on the market.

3. Survodutide — the GLP-1/glucagon dual

Survodutide is a dual GLP-1 and glucagon receptor agonist being co-developed by Boehringer Ingelheim and Zealand Pharma. The glucagon component adds liver fat burning to the appetite suppression of GLP-1.

The SYNCHRONIZE-1 Phase 3 trial completed in April 2026 with positive results: 16.6% mean weight loss at 76 weeks (higher dose) vs 3.2% on placebo. This is the first Phase 3 readout for any dual GLP-1/glucagon agonist. A FDA submission is expected in 2026-27.

4. MariTide — the once-monthly GIP antagonist

MariTide (maridebart cafraglutide) by Amgen is unique in two ways: it's dosed once monthly(not weekly), and it uses GIP receptor antagonism (blocking) rather than agonism (stimulating). Phase 2 results showed ~20% weight loss. The MARITIME Phase 3 program is underway with completion estimated January 2027.

5. Amycretin — the oral amylin

Amycretin by Novo Nordisk is an oral amylin receptor agonist — a daily pill that targets the satiety pathway through amylin, not GLP-1. Phase 3 trials are starting in 2026. If successful, amycretin could offer a pill-based option for patients who don't respond to or can't tolerate GLP-1 medications.

Mechanism comparison: how each drug class works

What this means for patients today

The pipeline is exciting, but the message is clear: don't wait. The drugs available today are highly effective:

• Zepbound (tirzepatide): ~20-22.5% weight loss — available now
• Wegovy HD (7.2 mg): 20.7% weight loss — available now
• Wegovy (2.4 mg): ~15% weight loss — available now
• Foundayo (orforglipron): ~12.4% weight loss, daily pill — available now
• Wegovy pill: ~13.6-16.6% weight loss, daily pill — available now

Starting treatment now means you can begin losing weight and improving your health immediately. If a pipeline drug like retatrutide or CagriSema becomes available and offers better results for your situation, you can switch with your healthcare provider's guidance. Waiting 1-2 years for a pipeline drug means losing valuable time for health improvement.

The competitive landscape: who owns what

Two companies dominate the GLP-1 space, but challengers are emerging:

• Eli Lilly: Zepbound, Mounjaro, Foundayo, retatrutide (pipeline), mazdutide (partnered)
• Novo Nordisk: Wegovy, Ozempic, Wegovy pill, Wegovy HD, CagriSema (pipeline), amycretin (pipeline)
• Amgen: MariTide (pipeline)
• Boehringer / Zealand: Survodutide (pipeline), petrelintide (partnered with Roche)
• Viking Therapeutics: VK2735 (early stage)

With 190 products in development, the obesity drug market is projected to reach $58 billion in 2026 and continue growing as new mechanisms and formats reach the market.

The bottom line

The GLP-1 pipeline is unprecedented in both scale and innovation. Retatrutide's 28.3% weight loss represents a potential new ceiling for pharmacological weight loss, while CagriSema's amylin mechanism offers a novel approach. But the drugs available today are already life-changing for millions. If you're considering GLP-1 treatment, start now — and keep an eye on the pipeline for future options.